GRACE :: Global Resource for Advancing Cancer Education

Acquired Resistance Patient Forum – September 6, 2014

Share
  • Patient Forum

 

We invite you to join us for the next patient forum:

The Acquired Resistance

Patient Forum

 For patients & caregivers living with
ALK, ROS1 or EGFR lung cancer

 to be held at the

Omni Parker House Hotel

60 School Street, Boston, Mass

Sept. 6, 2014 | 9 a.m. – 3:30 p.m.

Don’t delay!  Please register now!


Join GRACE and 100-200 patients and caregivers at the Acquired Resistance Patient Forum on September 6, 2014 in Boston, Massachusetts, where we will connect ALK, ROS1 and EGFR patients with leading oncologists, forefront in the field. Our faculty will speak about current treatment options and the future of care, and will learn directly from forum attendees about their experiences and concerns. Registration is $50.00 per person. 

Register now to reserve your space!   

View the agenda. 

Accommodations 
GRACE has reserved a room block at the Omni Parker House Hotel at a rate of $229/night, plus fees and taxes. To reserve your room, log onto omnihotels.com/bookyourstay and enter 090514ACQUIREDR into the “Group Code” box or call (800) 843-6664 and request the Acquired Resistance Patient Forum room block rate.

Click to register NOW for the Acquired Resistance Patient Forum

 

 

 

 


 Faculty

  • Bonnie AddarioBonnie Addario, Bonnie Addario Lung Cancer Foundation  (ALCF) was founded in 2006, but it really began long before its official start date when Bonnie received a Lung Cancer diagnosis and her life was redefined. Her prognosis was grim when she was diagnosed in 2004. Following a 14-hour surgery, a battery of nurses and doctors, an army of radiation and chemotherapy treatments, blood clots, procedures and tubes that invaded her formerly predictable life, Bonnie became a Lung Cancer survivor.  Since it’s founding, ALCF has grown into the first international collaborative entity of its kind, raising millions of dollars for Lung Cancer research and programs to support patients and their families.

  • Gideon Blumenthal Dr. Gideon Blumenthal, Food & Drug Administration, is the Clinical Team Leader and Scientific Liaison for Thoracic Malignancies in the Center for Drug Evaluation and Research at FDA.  Dr. Blumenthal is a board certified internist, hematologist, and oncologist.  He is also an attending physician at the Thoracic Malignancy clinic at the National Cancer Institute in Bethesda, Maryland. His research interests include developing novel endpoints and trial designs to expedite the development of safe and effective medicines for lung cancer patients. 
  • Craig in PA“CraigInPA,” Online Patient Advocate is a 3+ year survivor of stage IV lung cancer thanks to being an early participant in the first clinical trial for ROS1+ lung cancer patients.  Upon diagnosis, despite being a never-smoker in his mid-50’s with no risk factors, he turned his life-long passion for medical research toward lung cancer research and sharing that information with his peers in online forums in the hope that some might be helped as he has been.  Departing from the stereotype of a Wharton MBA with technology business career (albeit with a fair amount of sciences education, too), he found a calling helping others as an online patient-to-patient advocate and has become deeply appreciated by many patients and caregivers.
  • Dr. Robert Doebele Dr. Robert Doebele, University of Colorado  joined the faculty at University of Colorado Denver in July of 2008 as a member of the Thoracic Malignancies Program. He completed his Internal Medicine Residency and Medical Oncology Fellowship at the University of Chicago where he remained as an Instructor in 2007. Dr. Doebele is a recipient of the 2011 Boettcher Webb-Waring Biomedical Award and the 2013 V Foundation for Cancer Research, V Scholar Award.
  • Dr. Pasi Janne, Dana-Farber Cancer Institute  received his MD and PhD from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women’s Hospital and in medical oncology at DFCI in 2001. He currently works in the Lowe Center for Thoracic Oncology at DFCI. His main research interests include the study of epidermal growth factor receptor mutations in non-small cell lung cancer and their impact on the efficacy of EGFR-targeted therapeutic agents. 
  • Dr. Melissa Johnson Dr. Melissa Johnson, Lurie Comprehensive Cancer Center  is an Assistant Professor at Northwestern University’s Feinberg School of Medicine in Chicago. She trained at the University of Pennsylvania School of Medicine, followed by residency in Internal Medicine at New York Presbyterian Hospital/Weill Cornell Medical Center. She received her fellowship training in medical oncology at Memorial Sloan-Kettering cancer Center, where she received several ASCO merit awards for her clinical research efforts in thoracic oncology, and where she served as Chief Fellow. In addition to caring for lung cancer patients in her Chicago clinic, she leads clinical trials, including focusing on novel therapies for patients with an EGFR mutation, as well as other molecularly targeted therapies. She is also particularly interested in genetic mutations that may contribute to racial variations in lung cancer risk.
  •  Dr. NDr. Nate Pennellate Pennell, Cleveland Clinic is board certified medical oncologist who joined the staff of the Taussig Cancer Center in 2008. He specializes in the treatment of thoracic malignancies with a focus on lung cancer, and was appointed director of the TCI lung cancer medical oncology program in 2010.  Dr. Pennell’s research interests include clinical trials using novel therapies, with a goal of facilitating the movement of new treatments from the laboratory to the clinic.  He received his Ph.D. in neuroscience in 1998 and his M.D. in 2002 from the University of Florida College of Medicine in Gainesville, FL.  Dr. Pennell completed his internal medicine residency in 2005 at Brigham and Women’s Hospital in Boston, MA. His medical oncology fellowship training was completed in 2007 at the Dana Farber Cancer Institute.
  •  Dr.Greg ReilyDr. Greg Riely, Memorial Sloan Kettering Cancer Center  is board-certified medical oncologist who specializes in treating patients with lung cancer and thymic tumors (thymoma and thymic carcinoma). In addition to caring for men and women with these diseases, he works to develop new treatments by designing and conducting clinical trials. His clinical research focuses on the treatment of patients with thymic tumors as well as non-small cell lung cancer with specific mutations (EGFR, KRAS, BRAF, or EML4-ALK mutant non-small cell lung cancer).
  • Lecia SequistDr. Lecia Sequist, Massachusetts General Hospital studied chemistry at Cornell University. She received her MD from Harvard Medical School and trained in internal medicine at the Brigham and Women’s Hospital and in hematology/oncology at the Dana-Farber Cancer Institute, where she also received an MPH from the Harvard School of Public Health. She joined the faculty of the Center for Thoracic Cancers at the Massachusetts General Hospital Cancer Center in 2005 and has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer. She is currently an Assistant Professor of Medicine at Harvard Medical School. Dr. Sequist’s research focuses on studying novel targets and targeted agents for lung cancer treatment, particularly those that target the epidermal growth factor receptor (EGFR) and in detecting and studying the significance of tumor cells circulating in the bloodstream (circulating tumor cells, or CTCs). She aims to develop treatment algorithms for lung cancer that are more personalized than current strategies, utilizing targeted therapies specific to the patients’ cancer genotypes, and understanding how this may change over the courses of the disease.
  • Dr. Alice ShawDr. Alice Shaw, Massachusettes General Hospital is an Associate Professor of Medicine at Harvard Medical School, Attending Physician at Massachusetts General Hospital, and Clinical Investigator at MIT’s Koch Institute for Integrative Cancer Research.  She received her A.B. in Biochemistry from Harvard and her M.D. and Ph.D. degrees from Harvard Medical School.  She did her residency in Internal Medicine at Massachusetts General Hospital and completed a fellowship in Hematology/Oncology at Dana-Farber/Massachusetts General Hospital.  She completed her postdoctoral work in the laboratory of Dr. Tyler Jacks at MIT.   

    In addition to caring for patients with lung cancer, Dr. Shaw also performs clinical and translational research.  Her research focuses on anaplastic lymphoma kinase (ALK), ROS1 and RET rearrangements in non-small cell lung carcinoma (NSCLC).  She was the lead investigator for the global registration studies of crizotinib, which led to regulatory approval of crizotinib in advanced ALK-rearranged NSCLC.  She is currently the lead investigator for crizotinib in ROS1-rearranged NSCLC.  Her research focuses on elucidating mechanisms of resistance to targeted therapies, and she is currently leading several clinical trials and translational efforts aimed at overcoming resistance.

  • Jared Weiss, MDDr. Jared Weiss, University of North Carolina  is an Assistant Professor of Clinical Research for Hematology/Oncology at the University of North Carolina School of Medicine in Chapel Hill, NC. He received his Doctor of Medicine at Yale University School of Medicine in New Haven, CT and his B.S. in neuroscience at Brown University, in Providence, RI.  Dr. Weiss serves as the Vice President of the Board for GRACE.
  • Dr. H. Jack WestDr. H. Jack West, Swedish Cancer Institute, GRACE President and Founder, medical oncologist and Medical Director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington. He also serves as President of the Global Resource for Advancing Cancer Education (GRACE).  Dr. West received an M. Phil. in Experimental Biology from Cambridge University on a Fulbright Scholarship before returning to the US to undertake his medical training at Harvard Medical School in Boston, where he earned his MD magna cum laude and conducted research as a Howard Hughes Medical Student Fellow. He stayed in Boston for his internship and residency in internal medicine at Brigham and Women’s Hospital, then moved to Seattle for his fellowship in medical oncology at the Fred Hutchinson Cancer Research Center/University of Washington. He moved to the Swedish Cancer Institute in Seattle in late 2002, where he directs the medical oncology component of thoracic oncology program.
 

 

 

 

Click here for the full Agenda  (SUBJECT TO CHANGE).


Grace would like to thank the following organizations for their support of this forum:

Forum Champion:

Novartis Logo

Forum Partners:

Astra Zeneca

 

 Genentech logo

 

Advocacy Partners:

Bonnie Addario Lung Cancer Foundation

Lungevity

 Webcast Sponsors:

BI 

 Tote Bag Sponsors:

Clovis Oncology

 


Leave a Reply

Ask Us, Q&A
Share

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Recent GRACE Forum Topics

Recent GRACE Forum Replies

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243

Other Resources